Nanoparticle-Mediated Immune Modulation in Cancer Therapy

Nanoparticles have emerged as versatile platforms for reprogramming the immune landscape of tumours by co-delivering immunomodulators—such as adjuvants, cytokines or antigens—with high precision and controlled kinetics. By targeting key innate receptors, notably toll-like receptors (TLRs) on dendritic cells and tumour-associated macrophages, nanoparticle formulations can shift the balance from immunosuppressive to pro-inflammatory phenotypes. This approach improves antigen presentation, boosts cytotoxic T-cell infiltration and enhances checkpoint-blockade therapies, while reducing systemic toxicity. pH-responsive or biodegradable matrices permit on-site release within acidic endolysosomal compartments, whereas surface functionalisation and size tuning favour selective homing to tumour beds and draining lymph nodes. Overall, nanoparticle-mediated immune modulation integrates physicochemical engineering with immunological insight to generate more effective and safer cancer immunotherapies.

Research from Nature Portfolio

Biodegradable polymer microparticles co-encapsulating combinations of TLR agonists have been shown to generate synergistic innate and adaptive responses. Dual and triple formulations of TLR4, TLR7 and TLR9 ligands in pathogen-mimetic particles promoted dendritic cell maturation, enhanced antigen cross-presentation and shaped balanced Th1/Th2 humoral responses, laying a foundation for next-generation vaccine-adjuvant systems. In parallel, work on a small-molecule TLR7/8 agonist demonstrated that its stromal engagement in pancreatic tumours remodels the microenvironment by amplifying CD8+ T-cell infiltration, reducing regulatory T-cell frequency and attenuating cancer-associated cachexia, thereby nearly doubling survival in preclinical models.

Nanoparticle-Mediated Immune Modulation in Cancer Therapy publication trend

The graph below shows the total number of articles in nanoparticle-mediated immune modulation in cancer therapy across all publications each year (not limited to Nature Index journals).

Technical terms

Nanoparticle: A particle with dimensions between 1 and 100 nm used to encapsulate or display therapeutic agents for targeted delivery and controlled release.

Toll-like receptor (TLR): An innate immune receptor that recognises conserved molecular patterns and triggers pro-inflammatory signalling pathways.

Adjuvant: A substance that enhances the magnitude or quality of immune responses when co-administered with an antigen.

Tumour-associated macrophage (TAM): A macrophage within the tumour microenvironment that can adopt pro-tumour (M2) or anti-tumour (M1) activation states.

Nanogel: A hydrogel at the nanoscale, capable of encapsulating bioactive molecules and releasing them in response to environmental cues such as pH or enzymes.

References

1. The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nature Communications (2019).
2. Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy. Theranostics (2019).
3. Combinatorial Delivery of Dual and Triple TLR Agonists via Polymeric Pathogen-like Particles Synergistically Enhances Innate and Adaptive Immune Responses. Scientific Reports (2017).
4. Squaric Ester-Based, pH-Degradable Nanogels: Modular Nanocarriers for Safe, Systemic Administration of Toll-like Receptor 7/8 Agonistic Immune Modulators. Journal of the American Chemical Society (2021).
5. Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors. ACS Nano (2022).